The Osteoarthritis market growth is driven by factors like increase in the prevalence of Osteoarthritis, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Osteoarthritis market report also offers comprehensive insights into the Osteoarthritis market size, share, Osteoarthritis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Osteoarthritis market size growth forward.
Some of the key highlights from the Osteoarthritis Market Insights Report:
Several key pharmaceutical companies, including Novartis, Ampio Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Biosplice Therapeutics, Organogenesis, Kolon Tissuegene, Paradigm Biopharma, Novo Nordisk, Amzell, Nature Cell, Tissuetech, Techfields Pharma, Sorrento Therapeutics, Merck Kgaa/trialspark, Akl Research and Development, Medipost, Medivir, and others, are developing novel products to improve the Myelodysplastic Syndrome treatment outlook.
The total Osteoarthritis market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
As per DelveInsight analysis, the Osteoarthritis market is anticipated to witness growth at a considerable CAGR
The total market size of Osteoarthritis in the United States is expected to increase with a CAGR of 4.4% during the study period (2019–2032).
Strategise your business goals by understanding market dynamics @ Osteoarthritis Market Landscape
Osteoarthritis is the most common form of arthritis. Some people call it degenerative joint disease or “wear and tear” arthritis. It occurs most frequently in the hands, hips, and knees. Osteoarthritis is most likely to affect the joints that bear most of the weight, such as the knees and feet. Joints that the person uses a lot in everyday life, such as the joints of the hand, are also commonly affected. The main symptoms of osteoarthritis are pain and sometimes stiffness in the affected joints. The pain tends to be worse when the person moves the joint or at the end of the day. Osteoarthritis is a leading cause of disability and source of societal cost in older adults. With an aging and increasingly obese population, this syndrome is becoming even more prevalent than in previous decades.
Do you know the treatment paradigms for different countries? Download our Osteoarthritis Market Sample Report
Osteoarthritis Epidemiology Segmentation
DelveInsight’s Osteoarthritis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Osteoarthritis historical patient pools and forecasted Osteoarthritis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Osteoarthritis Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Age-Specific Osteoarthritis Prevalence
Gender-Specific Osteoarthritis Prevalence
Diagnosed and Treatable Cases of Osteoarthritis
Visit for more @ Osteoarthritis Epidemiological Insights
Osteoarthritis Treatment Market
Osteoarthritis, also known as degenerative joint disease, is typically the result of wear and tear and progressive loss of articular cartilage; it is most common in the elderly. Several pharmacologic treatments are available to manage knee OA-related pain and improve its functionality.
Common pharmacologic interventions to help alleviate knee OA symptoms include nonsteroidal anti-inflammatory drugs (NSAIDs), intra-articular corticosteroids, intra-articular hyaluronic acid, and opioids. The US FDA-approved sodium hyaluronate includes SUPARTZ (Smith & Nephew) – approved on January 24, 2001; ORTHOVISC (Anika Therapeutics) – approved on February 4, 2004; EUFLEXXA (Ferring Pharmaceuticals) – approved in 2005; and GEL-ONE Cross-linked Hyaluronate (Seikagaku Corporation) – approved in 2011. In October 2017, Flexion Therapeutics announced the US FDA approval of ZILRETTA for knee OA. The pivotal Phase III trial, on which the approval of Zilretta was based, showed that ZILRETTA significantly reduced OA knee pain for 12 weeks, with some people experiencing pain relief through Week 16.
The current developmental pipeline for knee OA is robust; several companies have initiated clinical trials investigating new treatment options or studying how to use existing treatment options better. The dynamics of the OA market are also anticipated to change in the coming years, owing to the rise in healthcare spending globally.
Osteoarthritis Therapy Assessment
ZILRETTA: Flexion Therapeutics/Pacira BioSciences
ZILRETTA is the first and only extended-release, intra-articular therapy for patients confronting OA knee pain. ZILRETTA employs proprietary microsphere technology combining triamcinolone acetonide commonly administered, immediate-release corticosteroid – with a poly lactic-co-glycolic acid (PLGA) matrix to provide extended pain relief. The pivotal Phase III trial, on which the approval of Zilretta was based, showed that Zilretta significantly reduced OA knee pain for 12 weeks, with some people experiencing pain relief through Week 16. In October 2017, Flexion Therapeutics announced the US FDA approval of Zilretta, the first and only extended-release, intra-articular injection for knee OA. In November 2022, company announced that launch of Phase III study in shoulder OA in 2023 and anticipating completion of study by 1H 2024.
CINGAL: Anika Therapeutics
CINGAL is the first and only commercially available combination viscosupplement and is currently being used successfully by physicians to provide rapid and long-lasting relief from pain and discomfort caused by OA for patients in a growing number of countries. CINGAL is a patented formulation composed of the company’s proprietary crosslinked sodium hyaluronate and triamcinolone hexacetonide. CINGAL is Anika’s third-generation viscosupplement to treat pain associated with knee OA, following its other products, Orthovisc and Monovisc. In June 2016, Anika Therapeutics announced the commercial launch of CINGAL in the European Union. In November 2022, company announced positive Phase III data of CINGAL 19-01 study, as per the company statement it plans meeting with FDA to discuss next steps for the US regulatory approval. Moreover the company is actively assessing options to advance CINGAL, including potential commercial partnerships in the US and select Asian markets.
TRIVISC: OrthogenRx / Avanos Medical
TRIVISC is from a class of products known as hyaluronic acid, sodium hyaluronate, or hyaluronan (HA), also referred to as viscosupplementation therapy. It is used in a nonsurgical procedure that helps supplement the viscous properties of the fluid in the knee joint. In November 2017, the company announced that the US FDA had approved TRIVISC for the treatment of knee OA in patients who failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics.
VISCO-3: Zimmer Biomet/Seikagaku Corporation
VISCO-3 is a solution made of highly purified sodium hyaluronate. Hyaluronan is a natural chemical found in the body and is found in particularly high amounts in joint tissues and in the fluid (synovial fluid) that fills the joints. In December 2015, Seikagaku Corporation (Tokyo) announced that the US FDA had approved VISCO-3 for the treatment of knee OA in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.
Osteoarthritis Key Companies
Personalized Stem Cells
Asahi Kasei Pharma
Taiwan Bio Therapeutics
Bone Therapeutics S.A
Taiwan Liposomal Company
For more information, visit Osteoarthritis Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Osteoarthritis Market Report:
11 Years Forecast
Descriptive overview of Osteoarthritis, causes, signs and symptoms, diagnosis, treatment
Comprehensive insight into Osteoarthritis epidemiology in the 7MM
Osteoarthritis marketed and emerging therapies
Osteoarthritis market drivers and barriers
Key Questions Answered in the Osteoarthritis Market Report 2032:
What was the Osteoarthritis market share distribution in 2019, and how would it appear in 2032?
What is the total Osteoarthritis market size and the market size by therapy across the 7MM for the study period (2019-32)?
What are the important findings from 7MM, and which country will have the greatest Osteoarthritis market size from 2019-32?
During the study period (2019-2032), at what CAGR is the Osteoarthritis market projected to expand at 7MM?
Table of Contents:
1 Osteoarthritis Market Key Comprehensive Insights
2 Osteoarthritis Market Report Introduction
3 Competitive Intelligence Analysis for Osteoarthritis
4 Osteoarthritis Market Analysis Overview at a Glance
5 Executive Summary of Osteoarthritis
6 Osteoarthritis Epidemiology and Market Methodology
7 Osteoarthritis Epidemiology and Patient Population
8 Osteoarthritis Patient Journey
9 Osteoarthritis Treatment Algorithm, Osteoarthritis Current Treatment, and Medical Practices
10 Key Endpoints in Osteoarthritis Clinical Trials
11 Osteoarthritis Marketed Therapies
12 Osteoarthritis Emerging Therapies
13 Osteoarthritis: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Osteoarthritis
16 Osteoarthritis Market Key Opinion Leaders Reviews
18 Osteoarthritis Market Drivers
19 Osteoarthritis Market Barriers
20 SWOT Analysis
22 DelveInsight Capabilities
23 About DelveInsight
Osteoarthritis Epidemiology 2032
DelveInsight’s “Osteoarthritis – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Osteoarthritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Osteoarthritis Pipeline 2023
“Osteoarthritis Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Osteoarthritis market. A detailed picture of the Osteoarthritis pipeline landscape is provided, which includes the disease overview and Osteoarthritis treatment guidelines.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States